Phase I/II – First Administration

443 trials 187 recruiting

Filter these 443 trials by condition, country, sponsor and more.

Open in Search →

Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically cons… Ended

2024-517566-42-00 Parkinson's disease
A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Ended

2022-501474-19-00 Non-Small Cell Lung Cancer
A first-in-human trial of safety and efficacy of GEN3017 in subjects with Hodgkin lymphoma or non-Hodgkin lymphoma Ended

2023-503348-15-00 Hodgkin lymphoma or non-Hodgkin lymphoma
Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with… Ended

2024-512353-24-01 Ovarian cancer
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Ac… Ended

2024-515258-25-00 advanced solid tumors with KRAS G12C mutation
DCC-3084 monotherapy in patients with solid tumors Ended

2024-517829-12-00 Solid tumors driven by the MAPK Pathway
A study to investigate the safety, tolerability, pharmacokinetics (PK), and preliminary anticancer activity of GSK4524101 alone or with nira… Ended

2024-520197-36-00 Neoplasms
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastro… Ended

2022-502087-21-00 Gastrointestinal Stromal Tumors (GIST)
Phase 1/2 Study of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD) Ended

2022-502096-32-00 Facioscapulohumeral muscular dystrophy (FSHD)
A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria Ended

2023-506963-32-00 Participants with Phenylketonuria
A Phase 1/2 Study of NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease Ended

2023-508138-33-00 Pulmonary emphysema